PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsGene therapy promising in Parkinson's patients

BioNews

Gene therapy promising in Parkinson's patients

Published 10 January 2014 posted in News and appears in BioNews 737

Author

Dr Kimberley Bryon-Dodd

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Patients in a clinical trial to treat Parkinson's disease with a form of gene therapy have showed signs of significant improvements in their motor-function, according to a report published in the Lancet...

Patients in a clinical trial to treat Parkinson's disease with a form of gene therapy have showed signs of significant improvements in their motor-function, according to a report published in the Lancet.

Fifteen advanced-stage Parkinson's patients (three from the UK and 12 from France) were followed up a year after being injected with low, mid and high doses of a modified virus containing genes required for brain cells to produce dopamine, as part of the phase I/II study. A lack of dopamine causes patients with Parkinson's to experience tremors and difficulty in coordinating their movement.

The researchers observed that after receiving the treatment the patients' scores on movement tests improved on average by 30 percent. The patients also reported having a better quality of life. Although the patients showed some side effects, overall the treatment was found to be safe and no serious side effects were observed.

Professor Stéphane Palfi, from the University of Paris and the lead author of the study, wrote that '[The treatment] was safe and well tolerated in patients with advanced Parkinson's disease', adding that, 'Improvement in motor behaviour was observed in all patients'. The researchers said scans have shown that dopamine was being produced in the patients where it wasn't before.

The treatment, called ProSavin, is a type of gene therapy and was developed by scientists working at Oxford BioMedica. Unlike more conventional therapies that involve taking a regime of pills to increase dopamine in the brain, ProSavin aims to offer a long-term treatment solution by getting brain cells to make their own dopamine. The modified virus transports three genes that code for a dopamine-producing enzyme into a part of the brain that controls movement.

Dr Kyriacos Mitrophanous, head of research at Oxford BioMedica, wrote in an email to Medical Daily that: 'This is the first gene therapy approach that delivers the three key enzymes in one vector required to convert cells in the brain to manufacture dopamine, the neurotransmitter that is depleted in Parkinson’s disease'. He added that, 'The long-lasting benefits we have seen to date give us great hope for this product and the underlying technology'.'

ProSavin was tested in only a small number of patients at this stage and the study lacked a placebo only control group to rule out a placebo effect. The absence of a placebo group means the results should be treated with caution, states a press release from Imperial College London. Further studies are required to demonstrate that it is more effective than current treatments and that the benefits are not due to the placebo effect.

Professor Nicholas Mazarakis, from Imperial College London and an author on the study, said: 'I'm very pleased that [ProSavin] has appeared to work in the clinic'.

He added: 'It has the potential to move to the next phase. It needs to be done in more people; we have to find the most effective dose, to further increase efficacy, and prove beyond doubt that this is not a placebo effect'.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
9 January 2015 • 2 minutes read

23andMe partners with Genentech in Parkinson's disease deal

by Rebecca Carr

23andMe, the personal genetics company, has announced an agreement with biotech company Genentech to identify new therapeutic targets for the treatment of Parkinson's disease...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
7 November 2014 • 2 minutes read

Stem cell therapy for Parkinson's restores dopamine in rats

by Rhys Baker

Researchers have reversed the effects of Parkinson's disease in rats, using human embryonic stem cells...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 October 2014 • 2 minutes read

Effects of common Parkinson's gene reversed in fruit flies

by Dr Vikki Burchell

A drug can reverse the effects of two Parkinson's disease-causing mutations in fruit flies, a study reports...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
29 November 2013 • 2 minutes read

Genetics and pesticide exposure 'double hit' might underlie Parkinson's for some

by Matthew Thomas

People with a particular genetic mutation may face greater risks of developing Parkinson's disease if exposed to certain pesticides, according to scientists...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
25 March 2013 • 2 minutes read

Study counters Parkinson's disease gene theory

by Helen Brooks

An experimental approach to treating Parkinson's disease may need to be reconsidered following evidence suggesting that it may make patients worse...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
5 March 2013 • 2 minutes read

Personal genomics company 23andMe awarded Parkinson's gene patent

by Ruth Saunders

23andMe, a personal genomics company, announced last week that it had been successfully awarded a patent for a gene variant which appears to protect against a high-risk mutation for Parkinson's disease...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
21 February 2013 • 2 minutes read

Gene therapy shows early success in Parkinson's trial

by Dr Kimberley Bryon-Dodd

A woman with Parkinson's disease is reportedly able to write again for the first time in 15 years after receiving pioneering gene therapy at Addenbrooke's Hospital, Cambridge. Mrs Shelia Roy took part in an early stage clinical trial of ProSavin - a treatment developed by biopharmaceutical company, Oxford BioMedica....

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Birth complications more likely in IVF babies

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
13 June 2022 • 2 minutes read

Drop in diversity of blood stem cells leads to old-age health issues

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Common virus may be cause of recent hepatitis cases in children

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

1 August 2022 • 2 minutes read

CRISPR genome editing treatments may raise cancer risk

1 August 2022 • 2 minutes read

Differences in IVF-conceived children's size disappear by adolescence

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856